> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# FDA Approves Expanded Repatha Use
- URL: https://www.fdaweb.com/fda-approves-expanded-repatha-use/
- Published: 2021-09-24T12:00:00.000Z
- Updated: 2026-09-14T17:16:02.000Z
- Author: David McFarland
- Tags: Biologics, #legacy-id-D5150219

FDA has approved an Amgen supplemental BLA for Repatha (evolocumab) injection as an add-on treatment to diet alone or together with certain other therapies for patients aged 10 years and older with heterozygous familial hypercholesterolemia (HeFH) and homozygous familial hypercholesterolemia (HoFH). Repatha works by recto reducing low-density lipoprotein cholesterol (LDL-C), also known as “bad cholesterol,” according to an FDA news [release](https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-add-drug-ages-10-rare-forms-high-cholesterol?utm%5Fmedium=email&utm%5Fsource=govdelivery). The agency previously approved Repatha to reduce the risk of certain complications of cardiovascular disease in adults, and as an add-on therapy to reduce LDL-C cholesterol levels in adults with HeFH and patients with HoFH based on studies in adults and pediatric patients aged 13 and older.